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PharmacodynamicsAbstract Combined administration of certain doses of opioid compounds with a non-steroidal
anti-inﬂammatory drug can produce additive or supra-additive effects while reducing unwanted
effects. We have recently reported that co-administration of metamizol with tramadol produces
antinociceptive effect potentiation, after acute treatment. However, none information about the
effect produced by the combination after chronic or repeated dose administration exists. The aims
of this study were to investigate whether the antinociceptive synergism produced by the combina-
tion of metamizol and tramadol (177.8 + 17.8 mg/kg, s.c. respectively) is maintained after repeated
treatment and whether the effects observed are primarily due to pharmacodynamic interactions or
may be related to pharmacokinetics changes. Administration of metamizol plus tramadol acute
treatment signiﬁcantly enhanced the antinociceptive effect of the drugs given alone (P< 0.05).
Nevertheless, this effect decreased about 53% after the chronic treatment (3 doses per day, for
4 days). No pharmacokinetic interaction between metamizol and tramadol was found under acute
treatment (P> 0.05). The mechanism involved in the synergism of the antinociceptive effect
observed with the combination of metamizol and tramadol in single dose cannot be attributed to
a pharmacokinetic interaction, and other pharmacodynamic interactions have to be considered.
On the other hand, when metamizol and tramadol were co-administered under repeated adminis-
trations, a pharmacokinetic interaction and tolerance development occurred. Differences found
Effect of tramadol on metamizol pharmacokinetics and pharmacodynamics 675in metamizol active metabolites’ pharmacokinetics (P< 0.05) were related to the development of
tolerance produced by the combination after repeated doses. This work shows an additional preclin-
ical support for the combination therapy. The clinical utility of this combination in a suitable dose
range should be evaluated in future studies.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Opioid drugs remain the common choice for the treatment of
pain of moderate to severe intensity. However, the usefulness
of these drugs in treating chronic pain is limited due to the
development of tolerance to the analgesic effect that occurs
after repeated administrations, resulting in escalation of the
dose administered and therefore to an increased incidence of
adverse effects (Gammaitoni et al., 2003; Domı´nguez-Ramı´re
z et al., 2010). A common strategy to maintain adequate anal-
gesic effects and to reduce the adverse effects is to combine
doses of opioid compounds with nonsteroidal anti-
inﬂammatory drugs (NSAIDs). In certain combinations of
these drugs, it has been shown that it is not only possible to
reduce the risk of incidence of adverse effects associated with
the administration of high doses of the individual drugs, but
also the antinociceptive effects are increased (Herna´ndez-
Delgadillo et al., 2003; Lo´pez-Mun˜oz et al., 2004). Although
some clinical and preclinical studies showing that combina-
tions between opioids and NSAIDs can produce analgesic
potentiation, little is known about the antinociceptive effects
of repeated administrations. Some studies have shown good
efﬁcacy of the combination of tramadol and metamizol under
preclinical conditions (Planas et al., 2003; Poveda et al., 2003).
Metamizol and tramadol are analgesic drugs with complex
mechanisms of action, extensively used in combination in the
management of acute postoperative pain in humans (Poveda
et al., 2003). The pharmacodynamic mechanism for the inter-
action between metamizol and tramadol could be attributed
partially to their participation in the opioidergic system
(Vasquez and Vanegas, 2000; Lo´pez-Mun˜oz et al., 2013a).
Other mechanisms such as the L-arginine-NO-cyclic GMP
pathway and interaction with N-methyl D-aspartic acid recep-
tors could be proposed to explain the antinociceptive syner-
gism observed with the combination of such drugs. In a
previous study, 25 different combinations of metamizol and
tramadol were analyzed using the model of ‘‘pain-induced
functional impairment in rat’’ (PIFIR) after a single dose
administration, and the results as antinociceptive effects were
additive or potentiative, for all the combinations studied
(Lo´pez-Mun˜oz et al., 2013a).
Tramadol is a central analgesic drug with a low afﬁnity for
opioid receptors. Tramadol is metabolized in the liver by two
principal pathways: O-demethylation to O-desmethyltramadol
(M1) by CYP2D6 and N-desmethylation to N-
desmethyltramadol (M2) by CYP2B6 and CYP3A4. Only
one of tramadol metabolites, M1, is pharmacologically active.
Its selectivity for l receptors has recently been demonstrated,
showing a higher afﬁnity for opioid receptors than the parent
drug (Scott and Perry, 2000). Metamizol is a nonsteroidal
anti-inﬂammatory drug that acts as an effective analgesic
and antipyretic agent. Metamizol is a pyrazolone derivativethat inhibits the synthesis of prostaglandins at central and
peripheral levels (Alves and Duarte, 2002; Ortiz et al., 2003),
and it is also known that its antinociceptive effects are medi-
ated at least in part by central mechanisms (Herna´ndez and
Vanegas, 2001). Metamizol is a pro-drug that undergoes
hydrolysis to yield 4-methylaminoantipyrine (MAA),
which is transformed in the liver by cytochrome CYP3A4
to 4-aminoantipyrine (AA) and by oxidation to 4-
formylaminoantipyrine (FAA). AA is acetylated to 4-
acetylaminoantipyrine (AAA). MAA and AA produce a
dose-dependent antinociceptive effect in arthritic rats (PIFIR
model), whereas the other metabolites are inactive (Lo´pez-
Mun˜oz et al., 2013b).
It may be possible that metamizol and tramadol could com-
pete for the same enzymes, causing changes in the concentra-
tions of metabolites of metamizol and consequently in the
pharmacological effects produced. The aims of this study were
to investigate the antinociceptive synergism produced by the
combination of metamizol and tramadol (17.8 + 177.8 mg/kg,
s.c. respectively) in an acute and chronic administration sched-
ules and if the effects produced are mainly due to pharmacody-
namic interactions or may be related to pharmacokinetic
changes in the two main active metabolites of metamizol.2. Materials and methods
2.1. Animals
Male Wistar rats [Crl (WI)fBR] from the Production Unit of
Laboratory Animal Species of the Metropolitan Autonomous
University, weighing 180–220 g, were used. Animals were
housed in an animal room with controlled temperature
(22 ± 2 C) under a light–dark cycle of 12 h. Rats were pro-
vided with standard chow (Purina Laboratory Rodent Diet
5001, Pet Food, Me´xico City, Me´xico) and water ad libitum.
In the 12 h before the experiments, food was withheld, leaving
only free access to water. Experiments were performed during
the light phase and animals were used only once.
All experimental procedures were approved by the local
Institutional Animal Care and Use Committee in accordance
with the Mexican federal regulations for the care and use of
laboratory animals NOM-062-ZOO-1999 (Mexican Ministry
of Health), the Guidelines on Ethical Standards for
Investigations of Experimental Pain in Animals
(Zimmermann, 1983), the Committee for Research and
Ethical Issues of the International Association for the Study
of Pain (Covino et al., 1980) and adhere to the Guide for
Care and Use of Laboratory Animals, Washington, D.C.
(2011). The number of experimental animals was kept to a
minimum. At the conclusion of the study, rats were euthanized
with CO2 to avoid unnecessary suffering.
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Tramadol hydrochloride was obtained from Rimsa
Laboratories (Guadalajara City, Mexico); Metamizol was pur-
chased from Sanoﬁ-Aventis (Mexico City, Mexico). Uric acid
was obtained from Sigma Chemical Co (St. Louis, MO,
USA) and suspended in mineral oil. Either metamizol or tra-
madol alone, or in combination was administered subcuta-
neously (s.c.), using isotonic saline solution as vehicle (0.9%
w/v). The drug solutions were freshly prepared and adminis-
tered at volume of 2-mL/kg body weight for metamizol or tra-
madol. The doses mentioned in the text refer to salts of these
substances.2.3. Study design
Animals were randomly distributed into three groups of 12
animals each. Group I was used for studying the pharmacody-
namics and pharmacokinetics of metamizol alone at different
administration schedules; animals were randomly distributed
into two subgroups of six each in which the antinociceptive
effects and the pharmacokinetics of MAA and AA metabolites
were studied after single-dose (MET) and after multiple-dosing
treatments (3 doses per day) during a period of 4 days (MET-
4D). On the day of the experiment, rats under this treatment
received a single dose of 177.8 mg/kg of metamizol. The
MET-4D group received three daily doses of metamizol
(177.8 mg/kg, per dose) during a period of 4 days.
Pharmacokinetics of MAA and AA and the antinociceptive
effects using the PIFIR model (Lo´pez-Mun˜oz et al., 1993) were
determined in the same animal. Blood samples were drawn in
the group after administration of the drug, immediately after
the antinociceptive effect was measured.
Group II was treated with the combination of metamizol
and tramadol following the same administration schedules
used for Group I. Animals in this group were randomly
distributed into two subgroups of six rats each and the
pharmacodynamics and pharmacokinetics of metamizol were
studied after the simultaneous administration of metamizol
(177.8 mg/kg) and tramadol (17.8 mg/kg) in a single dose
(MET+TRA) and after repeated dosing of metamizol and tra-
madol (177.8 + 17.8 mg/kg, 3 times/day) during a total period
of 4 days (MET+TRA-4D). Pharmacokinetics of MAA and
AA metabolites and the antinociceptive effects of metamizol
plus tramadol groups using the PIFIR model were determined
in the same animal and blood samples were drawn following
the same sampling scheme as in Group I. In the
MET+TRA-4D group, pharmacodynamic and pharmacoki-
netic studies were performed after the last dosing was
concluded.
Group III consisted of 12 animals divided into two sub-
groups of six rats each, in which the antinociceptive effects
of tramadol administered alone, were studied after single-
dose (TRA) and after multiple-dosing treatments during a
period of 4 days (TRA-4D). On the day of the experiment,
rats in TRA group received a single dose of 17.8 mg/kg of
tramadol. TRA-4D group received three daily doses of tra-
madol (17.8 mg/kg, per dose) during a period of 4 days.
No pharmacokinetic studies were conducted for this
group.2.4. Pharmacodynamic analysis
2.4.1. Arthritis induction
Antinociception was assessed using the PIFIR model in rat
(Lo´pez-Mun˜oz et al., 1993). Detailed methodology has been
previously described. Brieﬂy, under isoﬂurane anesthesia, rats
were injected with 50 lL of uric acid (30%) into the right knee
joint to induce nociception. Immediately afterward, an elec-
trode was attached to each hind-paw of the animals. Rats were
allowed to recover from anesthesia and then placed on a stain-
less steel cylinder of 30 cm diameter. This cylinder was rotated
at 4 rpm for periods of 2 min every 30 min in order to force the
animals to walk. The time of electrode contact on the cylinder
was recorded with a computer controlled data acquisition
system.
2.4.2. Behavioral assessment
After uric acid injection, rats developed progressive dysfunc-
tion of the injured limb. The time of contact of the injured hind
limb reached a zero value 2.5 h after injection with uric acid.
At this time, metamizol, tramadol or metamizol plus tramadol,
previously dissolved in 0.9% saline solution, was subcuta-
neously (s.c.) administered to the animals. The time of elec-
trode contact was recorded immediately before blood
sampling at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, and 4 h after
drug(s) administration. Antinociception was evaluated as the
recovery of the contact time of the injured limb. Data were
expressed as the functionality index percent (FI%), i.e., the
time of contact of injected limb divided by the time of contact
of the control left paw · 100. For the purpose of this study,
inducing nociception in the experimental animals was unavoid-
able. However, care was taken to avoid unnecessary suffering.
Rats were euthanized 8 h after administration of the drug(s)
when the last blood sample was taken.
2.5. Pharmacokinetic analysis
2.5.1. Blood sampling
On the day of the study, rats were cannulated approximately
30 min before uric acid injection and 3 h before the drugs were
administered. Rats were anesthetized as previously described
and the caudal artery was cannulated with a PE-10 cannula
(Clay Adams, Parsippany, NJ, USA) connected to a PE-50
cannula. The cannula was kept patent with heparinized saline
solution and stopped with a needle.
Rats were allowed to recover from anesthesia and the drugs
were administered subcutaneously. Blood samples were with-
drawn from the caudal artery at 0 h (before the administration
of the drug) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 h after
administration of the drug. The cannula was withdrawn and
the animal was sacriﬁced after the 8 h sample.
Blood samples were transferred to heparinized polypropy-
lene tubes. Plasma was separated by centrifugation at
3500 rpm for 10 min at 4 C and stored at 20 C until further
analysis. The total volume of blood taken from each animal
did not exceed 1.8 mL.
2.5.2. Sample preparation
Extraction of main active metabolites of metamizol from
plasma samples was conducted using a Solid Phase
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tioned by ﬂushing with 6 mL of methanol and 6 mL of distilled
water. 50–100 lL of plasma sample was loaded into the car-
tridge and allowed to stand for 5 min, washed with 0.4 ml of
water and then dried under vacuum. The analytes were eluted
with 3 mL of methanol, at a ﬂow rate of 1 mL/min. The eluate
was evaporated to dryness in a water bath at 45 ± 5 C under
a gentle stream of nitrogen. The residue was reconstituted in
50–100 lL of mobile phase and 20 lL was injected onto the
HPLC system for analysis.
2.5.3. Chromatographic conditions
Metabolite MAA and AA plasma concentrations were deter-
mined by high performance liquid chromatography (HPLC)
with UV detection (Domı´nguez-Ramı´rez et al., 2012). The
chromatographic system consisted of a Knauer high perfor-
mance liquid chromatograph (Berlin, Germany) equipped with
a Smartline pump 100, a Smartline PDA detector 2800 and a
Smartline auto sampler 3950. The chromatographic station
ClarityChrom V2.6.xx software was used for acquisition and
processing of data. The separation was performed on an
Alltech Platinum C18 column (5 lm) 250 · 4.6 mm (Alltech
Associates, Deer-ﬁeld, IL, USA); a Phenomenex security
guard column (4 · 0.3 mm C18 cartridge, Torrance, CA,
USA) was used before the analytical column. The mobile
phase consisted of a mixture of water–methanol–triethyla
mine–acetic acid (70.9:27.7:0.9:0.5, v/v/v/v) at pH 5, degassed
before use, and the ﬂow rate was 1 mL/min. Detection wave-
length was set at 254 nm. All the analyses were carried at room
temperature (25 C). This method was proved to be linear
(R2 > 0.99), precise (CV < 9%), reproducible (CV < 9%)
and accurate (RE < 6%) within a range of 1–100 lg/ml, for
MAA and AA metabolites.
2.6. Data analysis and statistics
2.6.1. Pharmacodynamic data analysis
Temporal effect courses for tramadol, metamizol, or the com-
bination of metamizol and tramadol was constructed by plot-
ting the antinociceptive effect (FI%) vs. time (h) for each
treatment and the area under the effect–time curve (AUCe)
was calculated by the trapezoidal rule (Gibaldi, 1991).
Comparisons were established using analysis of variance
(ANOVA) followed by Tukey’s test. A signiﬁcant difference
between the means was indicated by a value of P< 0.05.
2.6.2. Pharmacokinetic data analysis
MAA and AA metabolite concentration-time curves were con-
structed and evaluated by non-compartmental analysis. From
the time courses obtained, the following pharmacokinetic
parameters were determined: area under the curve from time
zero until 8 h after drug administration (AUC0–8h), area under
the curve from time zero to inﬁnity (AUC01), rate constant
of the terminal phase of elimination (b), half-life of elimination
(t½ b), maximum plasma concentration achieved (Cmax) and
total clearance (Cl/F). All parameters were obtained from
the individual curves for each metabolite and for each treat-
ment and the geometric mean was calculated. Non-
compartmental analysis was performed using WinNonlin v.
4.1 (Pharsight, Mountain View, CA, USA). Treatment effects
on pharmacokinetic parameters were assessed by one-wayANOVA after logarithmic transformation followed by
Tukey’s test. Statistical analysis was performed using SPSS
software v. 17.0 (SPSS Inc., Chicago, IL, USA). A P< 0.05
was considered statistically signiﬁcant.
2.6.3. Relationship between pharmacokinetics of the MAA and
AA metabolites and the antinociceptive effect
In order to investigate the existent relationship between MAA
and AA plasma concentrations and the antinociceptive effect
observed under different experimental treatments, mean FI%
was plotted against mean plasma concentrations of MAA or
AA metabolite at each time during a 4 h period after the
administration of the drug(s). Finally, cumulative area under
the effect–time curve (AUCe) vs. cumulative AUC plasma con-
centrations (AUCp) of each metabolite after the different
administration treatments were ﬁtted to an Emax sigmoid
model according to the Hill’s equation:
E ¼ Emax  C
c
Ec50 þ Cc
where E is the observed overall effect (AUCe), Emax is the the-
oretical maximal effect that can be attained (387.5 FI% h), C is
the area under the metabolite (MAA or AA) plasma
concentration-time curve (AUCp), EC50 is the area under
MAA or AA plasma concentration-time curve that induces
an effect equivalent to 50% of Emax and c is the response factor
(Hill coefﬁcient). The ﬁt model for the relation between plasma
concentration and antinociceptive effect was carried out using
GraphPad Prism program v. 4.0 (GraphPad Software, Inc.,
San Diego, CA, USA).
3. Results
3.1. Pharmacodynamic analysis
The intra-articular injection of uric acid resulted in the com-
plete dysfunction of the right paw in a period of approximately
2.5 h, which corresponded to FI%= 0. At this time (zero),
drugs were administered. At the doses of metamizol and tra-
madol used, no adverse effects that could interfere with the
course of the study or the recording of the data were observed.
The cumulative antinociceptive effect during the observation
period (4 h) was determined as AUCe in order to analyze the
whole antinociception effect elicited by TRA or MET or by
the MET+TRA and MET+TRA-4D schedules. Fig. 1 shows
the antinociceptive effects elicited by tramadol, metamizol and
the combination of metamizol and tramadol under different
schedules.
Table 1 shows the pharmacodynamic parameters obtained
after subcutaneous administration of tramadol (17.8 mg/kg),
metamizol (177.8 mg/kg) and the combination of metamizol
and tramadol under acute and chronic administrations (3
times/day/4 days). The MET group showed an estimated max-
imal effect of 89.95 ± 17.2 FI% h, whereas the value of
86.70 ± 5.6 FI% h for MET-4D demonstrates no apparent
tolerance development (P> 0.05). However, when tramadol
was administered alone (acute administration), the global
effect was 18.33 ± 1.6%IF h and the antinociceptive effect
at 4 h after administration was 0.83 ± 0.7 >%IF. The global
effect diminished signiﬁcantly to 11.9 ± 2%IF and the
antinociceptive effects diminished to zero respectively
Figure 1 Overall antinociceptive effects after a single dose of
177.8 mg/kg of metamizol (MET), 17.8 mg/kg of tramadol (TRA),
administered alone or the combination of the drugs (MET+TRA)
administered in single dose and in repeated once-daily doses for
4 days in arthritic rats. Data from temporal courses of the effect
were transformed in AUCe (FI%h). Values are mean
AUCe ± S.E.M. (n= 6).
#P< 0.05, TRA acute vs. chronic
treatment; *P< 0.05, MET+TRA acute vs. MET+TRA-4D;
n.s. P> 0.05, chronic vs. acute treatment of MET.
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ceptive effect of tramadol.
In the MET+TRA schedule, a higher AUCe compared to
that obtained with the MET or TRA schedules was observed
(239.17 ± 26.7 FI% h) as a result of a supra-additive effect
(P< 0.05). However, after the administration of
MET+TRA-4D treatment the effect was approximately
53% lower (112.00 ± 13.2 FI% h) than the overall effect
obtained with the MET+TRA treatment (P< 0.05), evi-
denced that tolerance development may occur with the drug
combination under this administration schedule. However,
the effect of the MET+TRA-4D treatment continues to be
higher than the effect produced by MET-4D (P< 0.05).
3.2. Pharmacokinetics of the metabolites of metamizol
Mean plasma concentrations of MAA and AA, found after
administration of metamizol alone (177.8 mg/kg) or inTable 1 Pharmacodynamic parameters obtained after subcutaneou
kg) and the combination of metamizol and tramadol under acute an
Treatment Global eﬃcacy ABCe (%h)
Acute administration
TRA 17.8 18.33 ± 1.6
MET 177.8 89.95 ± 17.2
MET+TRA 239.17 ± 26.7*
Chronic administration (3 times/day/4 days)
TRA 17.8 11.90 ± 2.0#
MET 177.8 86.70 ± 5.6
MET+TRA 112.00 ± 13.2#
* P 6 0.05 with respect to the theoretical sum of the individual effects.
# P 6 0.05 with respect to the acute treatment.combination with tramadol (17.8 mg/kg) in single or repeated
administration, were plotted as a function of time. No parent
drug (metamizol) concentrations were detected.
3.2.1. MAA pharmacokinetics
Time courses for MAA plasma concentrations are shown in
Fig. 2A and the corresponding pharmacokinetic parameters
are included in Table 2. No signiﬁcant differences between
the pharmacokinetic parameters for MAA obtained after the
administration of metamizol alone and in combination with
tramadol under acute treatments were found (P> 0.05).
However, signiﬁcant differences were observed in AUC01
after the MET-4D schedule compared with the MET+TRA-
4D treatment. Values decreased from 150.1 ± 25.4 lg h/mL
for MET-4D to 88.1 ± 4.8 lg h/mL for the MET+TRA-4D
treatment (P< 0.01), about a 60% of the initial value. b value
increased from 0.66 ± 0.13 h1 for the MET-4D treatment to
1.2 ± 0.09 h1 for MET+TRA-4D (P< 0.05). No signiﬁcant
pharmacokinetic differences (P> 0.05) were found when
MET-4D was compared with MET treatment. However, sig-
niﬁcant differences in both the AUC01 and AUC0–8h were
observed when the combination MET+TRA was compared
with the MET+TRA-4D treatment: the ﬁrst, with a decrease
from 166.6 ± 23.5 lg h/mL to 88.1 ± 4.8 lg h/mL (P<
0.01) and the second, from 133.8 ± 16.8 lg h/mL to
83.2 ± 4.7 lg h/mL. Similar differences in b and t½ b were
observed: the value of b increased from 0.28 ± 0.06 h1 to
1.2 ± 0.09 h1. With respect to the t½ b value, a signiﬁcant
decrease from 3.3 ± 0.7 h for the acute treatment to a value
of 0.6 ± 0.1 h for the repeated dosing treatment was observed.
It should be noted that differences were also found in the
corresponding clearance (Cl/F) values. The values ranged
from 1.2 ± 0.2 L/h/kg in the case of MET+TRA to
2.0 ± 0.1 L/h/kg for the MET+TRA-4D treatment.
3.2.2. AA pharmacokinetics
Time courses for AA plasma concentrations are shown in
Fig. 2B and the corresponding pharmacokinetic parameters
are shown in Table 2. No signiﬁcant differences (P> 0.05)
were observed in the pharmacokinetic parameters of AA after
MET vs. MET+TRA. Likewise, no signiﬁcant differences
(P> 0.05) in any AA pharmacokinetic parameter were found
in the comparison of MET-4D vs. MET+TRA-4D
treatments.s administration of tramadol (17.8 mg/kg), metamizol (177.8 mg/
d chronic administrations (3 times/day/4 days).
Tmax (h) Emax (%IF) E4h (%IF)
1.00 14.00 ± 1.3 0.83 ± 0.7
0.75 59.56 ± 11.6 7.00 ± 6.2
1.00 85.56 ± 7.9 34.69 ± 5.9
0.50 14.00 ± 2.7 0.00 ± 0.0
0.50 52.33 ± 6.6 0.83 ± 0.6#
0.75 66.33 ± 5.8# 5.88 ± 3.8#
Figure 2 Panel A: MAA plasma concentration–time curves.
Panel B: AA plasma concentration–time curves. Values represent
mean ± S.E.M of six individual readings (n= 6).
Table 2 Pharmacokinetic parameters for the two main active m
177.8 mg/kg of metamizol alone (MET) or in combination with 1
treatment for 4 days.
Parameter MET MET+T
4-methyl-amino-antipyrine (MAA)
ABC01 (lg h/mL) 145.3 ± 14.5 166.6 ±
ABC0–8h (lg h/mL) 125.2 ± 11.0 133.8 ±
b (h1) 0.42 ± 0.06 0.28 ±
t½ b (h) 1.9 ± 0.3 3.3 ±
Cmax (lg/mL) 85.5 ± 12.8 64.7 ±
Cl/F (L/h/kg) 1.3 ± 0.1 1.2 ±
4-amino-antipyrine (AA)
ABC01 (lg h/mL) 153.5 ± 15.0 120.9 ±
ABC0–8h (lg h/mL) 98.2 ± 6.1 80.8 ±
b (h1) 0.15 ± 0.02 0.18 ±
t½ b (h) 4.9 ± 0.7 4.8 ±
Cmax (lg/mL) 19.2 ± 1.0 16.6 ±
Cl/F (L/h/kg) 1.2 ± 0.1 1.6 ±
* PP 0.05.
** P 6 0.01.
*** P 6 0.001.
ns P> 0.05 between the groups of comparison (MET vs MET+TRA; M
MET+TRA-4D) from each metabolite. Data are expressed as the mean
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recorded as 153.5 ± 15.0 lg h/mL, which decreased signiﬁ-
cantly to 86.0 ± 13.4 lg h/mL for MET-4D. AUC0–8h also
showed a signiﬁcant reduction from 98.2 ± 6.1 lg h/mL to
63.0 ± 11.2 lg h/mL (P< 0.05).
With the comparison of MET+TRA with the
MET+TRA-4D treatment, signiﬁcant differences were also
found in b and t½ b values for AA metabolite when comparing
MET+TRA with the MET+TRA-4D treatment; b values
increased from 0.18 ± 0.03 h1 for MET+TRA to
0.30 ± 0.02 h1 for the MET+TRA-4D treatment (P<
0.05). Consequently, t½ b values, a decrease from 4.8 ± 1.0 h
for the MET+TRA to a value of 2.4 ± 0.2 h for the
MET+TRA-4D treatment were observed (P< 0.05).
3.3. Relationship between pharmacokinetics of the MAA and AA
metabolites and the antinociceptive effects
In order to establish the relationship between the pharmacoki-
netics of the metabolites MAA and AA and the antinociceptive
effect, FI% vs. each metabolite plasma concentrations graphs
were constructed. Results from different treatment schedules
after administration of metamizol alone or in combination
with tramadol are shown in Figs. 3 and 4 respectively.
For the MET and MET-4D schedules, the relationship
between the antinociceptive effect (FI%) and MAA metabolite
plasma concentrations was characterized by a counter clock-
wise hysteresis loop when data were connected in sequence
(Fig. 3A). On the other hand, the relationship between the
effect and AA metabolite plasma concentrations showed a
mixed behavior, whereas the MET schedule exhibits a clock-
wise hysteresis and the MET-4D treatment showed a counter
clockwise hysteresis (Fig. 3B).
Meanwhile, for the MET+TRA and MET+TRA-4D
schedules, the relationship was characterized by a clockwiseetabolites of metamizol after subcutaneous administration of
7.8 mg/kg of tramadol (MET+TRA), under acute or chronic
RA MET-4D MET+TRA-4D
23.5ns 150.1 ± 25.4ns 88.1 ± 4.8*,**
16.8ns 140.6 ± 25.4ns 83.2 ± 4.7*,*
0.06ns 0.66 ± 0.13ns 1.20 ± 0.09**,***
0.7ns 1.4 ± 0.4ns 0.6 ± 0.1ns,*
11.1ns 78.2 ± 5.3ns 88.5 ± 7.2ns,ns
0.2ns 1.4 ± 0.3ns 2.0 ± 0.1ns,**
14.3ns 86.0 ± 13.4** 87.5 ± 9.0ns,ns
10.4ns 63.0 ± 11.2* 65.5 ± 10.1ns,ns
0.03ns 0.31 ± 0.07ns 0.30 ± 0.02ns,*
1.0ns 2.9 ± 0.6ns 2.4 ± 0.2ns,*
2.4ns 18.3 ± 1.9ns 18.4 ± 2.1ns,ns
0.2ns 2.4 ± 0.5ns 2.1 ± 0.2ns,ns
ET-4D vs MET+TRA-4D; MET vs MET-4D and MET+TRA vs
± S.E.M. (n= 6).
Figure 3 Mean plasma concentration–antinociceptive effect
relationship for MAA (panel A) and AA (panel B) metabolites
after s.c. administration of a single dose of metamizol (MET) and
chronic treatment for 4 days (MET-4D). Values are
mean ± S.E.M. (n= 6).
Figure 4 Mean plasma concentration–antinociceptive effect
relationship of MAA (panel A) and AA (panel B) metabolites
after s.c. administration of metamizol plus tramadol in a single
dose (MET+TRA) and chronic treatment for 4 days
(MET+TRA-4D). Values are mean ± S.E.M. (n= 6).
680 L.A. Moreno-Rocha et al.hysteresis loop for both MAA and AA metabolites
(Fig. 4A and B), except for the MET+TRA schedule where
a counter clockwise hysteresis loop was observed between
the effect and the MAA plasma concentrations (Fig. 4A).
Finally, the cumulative areas under the effect–time curve
were plotted against the cumulative areas under the curve of
metabolite plasma concentrations (Figs. 5 and 6). Data for
each treatment were ﬁtted to an Emax sigmoid model since in
all cases a good ﬁt (R2 > 0.99) was observed.
Fig. 5 shows the relationship between mean overall effect
(AUCe) and mean metabolite (MAA or AA) plasma concen-
trations vs. time area under the curve (AUCp) up to 4 h after
the administration of metamizol alone under different admin-
istration schedules (Group I). AUCe for the MAA metabolite
in a single dose attained a maximum value of 93.75 FI% h for
an AUCp of 90 lg h/mL (Fig. 5A). The overall effect was
sustained during chronic treatments. Fig. 5B shows the rela-
tionship between the effects observed (AUCe) and the AA
metabolite concentrations (AUCp) after the administration of
the drug under the two different administration schedules
(MET and MET-4D).
Fig. 6 shows the relationship between AUCe and AUCp up
to 4 h after the administration of metamizol in combinationwith tramadol also under different administration schedules
(Group II). The overall effects in this comparison decreased
signiﬁcantly in 51% of the effect during the MET+TRA-4D
treatments.
4. Discussion
4.1. Antinociceptive effect of the combination of metamizol and
tramadol
The combination of metamizol and tramadol (177.8 +
17.8 mg/kg) was selected from a total of 25 combinations stud-
ied (Lo´pez-Mun˜oz et al., 2013a) because this proportion gives
an adequate antinociceptive effect and presents fewer side
effects than other combinations. The results obtained after
administration of the combination of metamizol and tramadol
after a single dose, conﬁrmed the potentiation of the antinoci-
ceptive effect elicited by the drugs given alone (P< 0.05).
Similar results were found with this combination using the
‘‘plantar test model’’ (Moreno-Rocha et al., 2012).
Development of tolerance to antinociceptive effect of tra-
madol was observed when the drug was administered alone
Figure 5 Data obtained after administration of metamizol alone
in a single and chronic treatment ﬁtted to the Emax model. Symbols
represent mean MAA (panel A) and AA (panel B) plasma
concentrations of six rats ± S.E.M.
Figure 6 Data obtained after administration of metamizol plus
tramadol in a single and chronic treatment ﬁtted to the Emax
model. Symbols represent mean MAA (panel A) and AA (panel B)
plasma concentrations of six rats ± S.E.M.
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with metamizol alone under the same conditions; however in
this case, although the duration of the effect was diminished,
descending to a value near zero at 2 h after the administration
of the drug on the last treatment day, the maximal effect was
the same as for metamizol given alone in single dose. The
development of tolerance to the antinociceptive effect was sig-
niﬁcantly increased with the drug co-administration of both
drugs. An increase in the rate of development of tolerance to
the antinociceptive effect of metamizol co-administered with
tramadol was previously reported using the plantar-test model
(Moreno-Rocha et al., 2012). Nevertheless, when the effect
attained by the combination after chronic treatment was com-
pared with the effect of the individual drugs after the 4-day
treatment, an increase in the global effect was observed
(P< 0.05), which is equivalent to the sum of the individual
effects (additive effect).
The pharmacodynamic mechanism for the interaction
between metamizol and tramadol could be partially attributed
to the participation of mechanisms such as the L-arginine-NO-
cyclic GMP pathway and interaction with N-methyl D-aspartic
acid receptors (Lo´pez-Mun˜oz et al., 2013a). Additionally, sev-
eral reports indicate that the antinociceptive effects produced
by metamizol are due, at least in part, to the release ofendogenous opioids in the descending pain pathways
(Herna´ndez and Vanegas, 2001), and this could also explain
the development of tolerance observed. However, other phar-
macokinetic interactions could be present, which are discussed
afterward.
4.2. Pharmacokinetics of the main active metabolites
of metamizol
In this study, possible changes in the pharmacokinetics of
MAA or AA metabolites in rats, which could explain the phar-
macological effects observed (antinociceptive and tolerance
development) after administration of metamizol alone and in
combination with tramadol, under acute and chronic treat-
ments, were investigated. To achieve this, the pharmacokinet-
ics of MAA and AA metabolites, under the four treatments
described, were followed. After the administration of the
MET schedule, pharmacokinetic parameters for MAA and
AA were calculated from data obtained by a non-
compartmental analysis (Table 1). This is consistent with ear-
lier studies in which the metabolite pharmacokinetics have
been described (Vlahov et al., 1990). Under these conditions,
the pharmacokinetic of metamizol in rats, is similar in some
aspects with some results obtained in studies conducted in
682 L.A. Moreno-Rocha et al.humans; i.e., the maximum plasma concentration of MAA
after a single administration of MET was 5–10 times higher
compared to other metabolites (Nogami et al., 1970). It can
be said that the pharmacokinetics of metamizol in acute treat-
ment vary among species in parameter values obtained, but
not in the relative proportion of the metabolites formed.
Pharmacokinetic parameters obtained in this study in rats
could not be compared with other studies, as scarce informa-
tion was found.
When comparing the parameters obtained with the admin-
istration of the MET with the data of the MET+TRA sched-
ule, no differences in the pharmacokinetic parameters for
MAA or AA, between both treatments were found
(P> 0.05), showing that tramadol does not modify the phar-
macokinetics of metamizol when administered together in a
single dose (Table 1). It can be observed that although there
is an increase in MAA metabolite’s elimination half-life,
together with a decrease in b value, there is not enough evi-
dence to show that a signiﬁcant change in the pharmacokinet-
ics of this metabolite exists (P> 0.05). Similar results were
obtained after administration of the combination of morphine
and metamizol, in acute treatment (Domı´nguez-Ramı´rez et al.,
2012). So, it can be said that the synergism of the antinocicep-
tive effect observed with the combination of metamizol and
tramadol (acute treatment) cannot be attributed to a pharma-
cokinetic interaction. Other pharmacodynamic interactions as
the involvement of the L-arginine-nitric oxide-GMPc pathway
and the activation of opioidergic system should be considered
(Moreno-Rocha et al., 2012).
Although no statistical differences were found for MAA
pharmacokinetics, between MET and MET-4D schedules, in
the case of AA metabolite, which is formed by oxidation of
MAA, via CYP2D6 system, the areas under the curve
decreased signiﬁcantly (P< 0.05), even when the decrease in
b or half-life time, was not statistically signiﬁcant (P> 0.05).
This may partly explain the decrease in the effect of metamizol
in chronic treatment since it is known that AA shows a similar
antinociceptive activity to that of MAA (Lo´pez-Mun˜oz et al.,
2013b).
Currently there are no pharmacokinetic studies including
the pharmacokinetics of metamizol in rats after a chronic
treatment schedule, so this study appears to be the ﬁrst to
make this comparison. Nevertheless, a study carried out in
human volunteers, with single (0.75, 1.5 and 3 g) and multiple
doses (1 g/3 times/day/7 days) administrations, showed a
change in the metabolism of MAA, to preferably form AA,
instead of FAA (Levy et al., 1995). It could be assumed that
the increase in the elimination process of AA is possibly due
to the induction of this particular metabolic pathway by a
mechanism that has not been clariﬁed yet.
The decreases in the areas under the curve of the active
metabolite AA after repeated treatment of metamizol may also
explain the decreased antinociceptive effect of metamizol
under the dosing schedule employed, since the decrease may
be accompanied by the formation of inactive metabolites
(mainly AAA), which is ﬁnally excreted by the kidneys.
When the combination of metamizol and tramadol was
administered in single dose, no signiﬁcant differences were
found when comparing the pharmacokinetic parameters of
metamizol alone. Unlike the above, the comparison of the
combined treatment using the multiple dose schedule showed
signiﬁcant differences in the pharmacokinetics of the activemetabolites, compared to the single dose treatment. This was
observed in most of the pharmacokinetic parameters for the
two main active metabolites (MAA and AA) of metamizol. b
and Cl/F values of MAA metabolite increased signiﬁcantly,
resulting in a signiﬁcant decrease in the AUC0–8, AUC01
and t½ b values. This should be explained by an induction
of the biotransformation mechanisms of metamizol, as well
as the development of tolerance observed with the combina-
tion in a chronic treatment schedule. In this regard, Saussele
et al., in 2007 demonstrated an increase in the expression of
some cytochromes (CYP2B6 and CYP3A4) in patients treated
with metamizol for a long time, suggesting that there is a
potential mechanism of induction of metamizol and its active
metabolite AA similar to that found in phenobarbital over
some drugs or its own metabolism (Saussele et al., 2007).
The development of tolerance observed with the combination
could therefore be explained by the induction of these elimina-
tion pathways not only for metamizol itself but also on the
metabolism of tramadol.
Finally, it should be mentioned that the frequency of the
administration impacts directly on the appearance of the
development of tolerance of metamizol either alone or com-
bined with this particular opioid drug. Apparently there is
no rule that indicates whether the combination of metamizol
with an opioid invariably will result in the development of
tolerance. All depend on the type of opioid, the proportions
employed and the administration schedule. Added to this,
various pharmacodynamic mechanisms of the compounds
contribute to the variability of responses. Up to this moment,
however, the mechanisms underlying antinociceptive potenti-
ation and tolerance development for the metamizol plus tra-
madol combination are not fully clear and deserve further
investigation.4.3. Relationship between pharmacokinetics of the main active
metabolites of metamizol and the antinociceptive effects
When the antinociceptive effect (FI%) was plotted against
metabolite plasma concentrations after acute treatment, a hys-
teresis was displayed (Figs. 3 and 4). As seen, a counter-
clockwise loop was observed, which indicates the lack of a
direct relationship. It can be assumed that the metabolite
appearance is delayed into the pharmacodynamic effect site
at a slower rate than that in which it appears in plasma.
Several explanations have been proposed for this performance,
including the formation of active metabolites, or an effect com-
partment different from those detected by conventional phar-
macokinetic analysis (Remington and Gennaro, 2006;
Louizos et al., 2014). The possibility of active metabolites for-
mation cannot be discarded since the AA metabolite that is
formed from MAA, also shows a high pharmacological activ-
ity (Lo´pez-Mun˜oz et al.,, 2013b). On the other hand, the rela-
tionship between functionality index (FI%) and metabolite
plasma concentration shown by metamizol plus tramadol com-
bination groups, showed a clockwise hysteresis loop that may
be the result of tolerance development by the presence of
antagonistic metabolites that are formed as the drug is metab-
olized, or down-regulation of receptors and feedback regula-
tion (Kwon, 2001).
Finally, when the relationship between the AUCe and
AUCp of MAA and AA metabolites was ﬁtted to the Emax
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satisfactory correlation (R2 > 0.99) was found. AUCe is con-
sidered to reﬂect the overall antinociceptive effect for the
whole experimental observation, whereas AUCp is referred to
the total amount of drug (or metabolite) in systemic circula-
tion along the same time interval. Both parameters can be
adequately related in the case of drugs with indirect effects
(Domı´nguez-Ramı´rez et al., 2010). The slope for
MET+TRA-4D treatment curves decreased slightly when
compared to MET+TRA (Fig. 4A) for AA but the difference
was not signiﬁcant (P> 0.05). The maximum effect estimated
from de Emax model was near 250 FI% h for MET+TRA for
both metabolites and diminished about to 100 FI% h after the
MET+TRA-4D schedule, which shows the relationship
between the diminution of metabolites concentration and the
effect observed, it is to say, the development of tolerance.
5. Conclusions
The results indicate that when the combination metamizol and
tramadol (177.8 + 17.8 mg/kg) is administered in single dose,
a potentiation of the antinociceptive effect is observed, while
the repeated administration of metamizol and tramadol leads
to the development of tolerance to the antinociceptive effect
of the drugs. Although less pronounced than that observed
with the co-administration of both drugs, a development of
tolerance was found for metamizol and tramadol given indi-
vidually, under repeated administration. No pharmacokinetic
interaction was observed between metamizol and tramadol
when co-administered in single dose. On the contrary, when
metamizol and tramadol were given in combination under
repeated doses administration, a pharmacokinetic interaction
was observed.
It is possible that changes in the antinociceptive effect of the
combination after chronic treatment are due in part to an
induction in the elimination process (biotransformation and
renal excretion) of metamizol. It is likely that the decrease in
plasma concentrations of the active metabolites MAA and
AA may be related to the decrease in the antinociceptive effect
of the combination of tramadol and metamizol after repeated
doses.
An increased tolerance development for the antinociceptive
effect of tramadol was conﬁrmed after the administration of
metamizol (177.8 mg/kg) under chronic treatment for 4 days.
Pharmacokinetic changes were found after chronic treatments
and also contributed to the rapid onset of tolerance develop-
ment of the antinociceptive effect of tramadol.
This work shows additional preclinical support for the
combination therapy, especially of combinations involving
the use of NSAIDs whose use is widespread. It requires cau-
tion when selecting a particular combination, especially for
chronic pain treatment. Overall, the usefulness of the combina-
tion depends on the treatment scheme used and the balance
between effectiveness and the occurrence of adverse effects
observed. The clinical utility of this combination in a suitable
dose range should be evaluated in future studies.
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